Explore

Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal
Reuters Reuters
Regeneron drops after skin cancer treatment fails late-stage trial

Regeneron drops after skin cancer treatment fails late-stage trial

By Christy Santhosh May 18 (Reuters) - Regeneron's shares fell 12% in morning trade on Monday after the company's experimental treatment missed the main goal in a late-stage trial for patients with a type of skin cancer.
Trendline Trendline
Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch

Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch

Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch
Trendline Trendline
Harbour BioMed Unveils Promising Preclinical Data for AI-Enabled Drug LET003 Targeting Obesity

Harbour BioMed Unveils Promising Preclinical Data for AI-Enabled Drug LET003 Targeting Obesity

Harbour BioMed Unveils Promising Preclinical Data for AI-Enabled Drug LET003 Targeting Obesity
Trendline Trendline
FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
Atisama Therapeutics Advances RB042 in Phase 1 Trial and Appoints New Board Chair

Atisama Therapeutics Advances RB042 in Phase 1 Trial and Appoints New Board Chair

Atisama Therapeutics Advances RB042 in Phase 1 Trial and Appoints New Board Chair
Trendline Trendline
Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion

Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion

Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion
Trendline Trendline
NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials

NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials

NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials
Trendline Trendline
FDA Halts Aardvark Therapeutics' Prader-Willi Drug Trials Over Cardiac Concerns

FDA Halts Aardvark Therapeutics' Prader-Willi Drug Trials Over Cardiac Concerns

FDA Halts Aardvark Therapeutics' Prader-Willi Drug Trials Over Cardiac Concerns
Trendline Trendline
Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress

Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress

Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress
Trendline Trendline
Arna Pharma and Slate Run Pharmaceuticals Launch Joint Venture and First Product

Arna Pharma and Slate Run Pharmaceuticals Launch Joint Venture and First Product

Arna Pharma and Slate Run Pharmaceuticals Launch Joint Venture and First Product